Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + pseudoephedrine is a fixed-dose combination of two active ingredients commonly used to relieve symptoms associated with upper respiratory tract infections, such as headache, fever, body aches, nasal congestion, and sinus pressure. Paracetamol (also known as acetaminophen) acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Pseudoephedrine is a sympathomimetic amine that acts primarily as an agonist at alpha adrenergic receptors in the nasal mucosa, causing vasoconstriction which reduces swelling and congestion. The combination provides both pain relief/fever reduction from paracetamol and decongestant effects from pseudoephedrine[1][5]. It is widely available under various brand names for over-the-counter use in cold, flu, or allergy-related conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + pseudoephedrine.